Dyadic International (NASDAQ:DYAI – Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), Zacks reports. The company had revenue of $0.82 million during the quarter, compared to the consensus estimate of $1.60 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter in the prior year, the firm earned ($0.24) EPS.
Dyadic International Price Performance
Shares of NASDAQ DYAI opened at $1.35 on Friday. The firm has a market capitalization of $39.95 million, a P/E ratio of -5.87 and a beta of 0.95. The firm’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.42. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. Dyadic International has a 1-year low of $0.93 and a 1-year high of $2.67.
Institutional Trading of Dyadic International
A hedge fund recently raised its stake in Dyadic International stock. Bank of America Corp DE grew its position in shares of Dyadic International, Inc. (NASDAQ:DYAI – Free Report) by 16,146.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,132 shares of the biotechnology company’s stock after acquiring an additional 26,965 shares during the quarter. Bank of America Corp DE owned about 0.09% of Dyadic International worth $47,000 as of its most recent filing with the Securities & Exchange Commission. 27.95% of the stock is owned by hedge funds and other institutional investors.
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
Further Reading
- Five stocks we like better than Dyadic International
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Archer Aviation Stock Sees Surge in Institutional Buys
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- These 4 Stocks Offer High Upside in the AI Data Center Boom
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- How Can Tomahawk 6 Contribute to Broadcom’s AI Growth Story?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
